Stock message boards
MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Interesting MPEL Put Options For December 12th
Thursday, October 30, 11:36 AM ET, by Market News Video Staff

Investors in Melco Crown Entertainment Ltd (MPEL) saw new options become available today, for the ...

One Put, One Call Option To Know About for Johnson & Johnson
Monday, November 3, 12:19 PM ET, by Market News Video Staff

Consistently, one of the more popular stocks people enter into their stock options watchlist at ...

Johnson & Johnson Popular Amongst Latest 13F Filers
Monday, November 3, 1:35 PM ET, by Market News Video Staff

At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F ...

iShares S&P 500 Growth ETF Experiences Big Inflow
Thursday, November 6, 11:07 AM ET, by Market News Video Staff

Symbols mentioned in this story: IVW, JNJ, GOOGL, CMCSA Exchange traded funds (ETFs) trade just ...

Interesting January 2015 Stock Options for Johnson & Johnson
Monday, November 10, 12:11 PM ET, by Market News Video Staff

Consistently, one of the more popular stocks people enter into their stock options watchlist at ...

  More articles:  1 2 3 4 5 6 7 next »

EEN at Discount to NAV, Largest Holding Crucell N.V. ADR

By Market News Video Staff, Friday, October 8, 8:07 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

The Guggenheim EW Euro-Pacific LDRs ETF (EEN) - formerly the Claymore/BNY Mellon EW Euro-Pac LDRs ETF - appears to be trading at a discount to NAV. According to the last reported NAV value (EEN.NV), the NAV per share is showing $19.2099 as of the time this article is being published. The closing price on EEN from yesterday was $19.25, placing the ETF at a 3.7% discount to NAV.

The top holding of this ETF is Crucell N.V. (CRXL). On October 6, Johnson & Johnson (NYSE:JNJ) and Crucell N.V. announced an agreement whereby Johnson & Johnson would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer.

The ETF also holds Elan Corp (ELN), Melco Crown Entertainment (NASDAQ:MPEL), amongst other ADRs.


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   According   CRXL   Claymore   Corp   Crown   Crucell   Definition   Definitions   ETFs   Entertainment   Euro   Exchange   Fund   Johnson   LDRs   MPEL   Market   Melco   NYSE   October   Stock   Traded   acquire   agreement   already   also   amongst   announced   appears   approximately   being   closing   discount   does   equity   formerly   from   holds   last   offer   published   reported   showing   tender   that   this   time   trading   value   would
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

EEN at Discount to NAV, Largest Holding Crucell N.V. ADR | Market News Video | Copyright © 2008 - 2014, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.